{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:10:28Z","timestamp":1790230228378,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.jaad.2016.12.004","type":"journal-article","created":{"date-parts":[[2017,2,4]],"date-time":"2017-02-04T17:15:41Z","timestamp":1486228541000},"page":"745-753.e19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":126,"title":["Janus kinase inhibitors in dermatology: A systematic review"],"prefix":"10.1016","volume":"76","author":[{"given":"Rony","family":"Shreberk-Hassidim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuval","family":"Ramot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Zlotogorski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2016.12.004_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.bcp.2011.12.024","article-title":"The many faces of Janus kinase","volume":"83","author":"Seavey","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jaad.2016.12.004_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(02)00398-0","article-title":"Signaling through the JAK\/STAT pathway, recent advances and future challenges","volume":"285","author":"Kisseleva","year":"2002","journal-title":"Gene"},{"key":"10.1016\/j.jaad.2016.12.004_bib3","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1136\/ard.2006.060822","article-title":"Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak\/STAT transcription factors from patients with rheumatoid arthritis","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2016.12.004_bib4","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clim.2010.05.003","article-title":"Analysis of JAK2 and STAT3 polymorphisms in patients with ankylosing spondylitis in Chinese Han population","volume":"136","author":"Chen","year":"2010","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaad.2016.12.004_bib5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1053\/j.gastro.2008.10.032","article-title":"Investigation of Crohn\u2019s disease risk loci in ulcerative colitis further defines their molecular relationship","volume":"136","author":"Anderson","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2016.12.004_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/B978-0-444-62652-3.00004-1","article-title":"Advances in the discovery of selective JAK inhibitors","volume":"52","author":"Menet","year":"2013","journal-title":"Prog Med Chem"},{"key":"10.1016\/j.jaad.2016.12.004_bib7","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2016.12.004_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/exd.12265","article-title":"Jakpot! New small molecules in autoimmune and inflammatory diseases","volume":"23","author":"Ghoreschi","year":"2014","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-207201","article-title":"Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors","volume":"75","author":"Gao","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2016.12.004_bib10","doi-asserted-by":"crossref","first-page":"e0164080","DOI":"10.1371\/journal.pone.0164080","article-title":"JAK3 as an emerging target for topical treatment of inflammatory skin diseases","volume":"11","author":"de Medeiros","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.jaad.2016.12.004_bib11","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.4049\/jimmunol.1400205","article-title":"Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23\/IL-17 axis","volume":"193","author":"Works","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2016.12.004_bib12","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.4049\/jimmunol.0804063","article-title":"JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL\/J mice","volume":"183","author":"Chang","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2016.12.004_bib13","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/jid.2009.25","article-title":"Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis","volume":"129","author":"Boy","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib14","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib15","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jaad.2016.07.040","article-title":"Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis","volume":"75","author":"Feldman","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib16","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial","volume":"172","author":"Bissonnette","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2016.12.004_bib18","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/1346-8138.13258","article-title":"Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: a randomized, double-blind, phase 3 study","volume":"43","author":"Asahina","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.12266","article-title":"A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","volume":"169","author":"Ports","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib20","first-page":"777","article-title":"Randomized pilot clinical trial of tofacitinib solution for plaque psoriasis: challenges of the intra-subject study design","volume":"14","author":"Ports","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12895-016-0051-4","article-title":"Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial","volume":"16","author":"Papp","year":"2016","journal-title":"BMC Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib22","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib23","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/bjd.13994","article-title":"Downmodulation of key inflammatory cell markers with a topical Janus kinase 1\/2 inhibitor","volume":"173","author":"Punwani","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib24","doi-asserted-by":"crossref","first-page":"e1500973","DOI":"10.1126\/sciadv.1500973","article-title":"Pharmacologic inhibition of JAK-STAT signaling promotes hair growth","volume":"1","author":"Harel","year":"2015","journal-title":"Sci Adv"},{"key":"10.1016\/j.jaad.2016.12.004_bib25","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2016.12.004_bib26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","article-title":"Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib","volume":"2","author":"Jabbari","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jaad.2016.12.004_bib27","first-page":"e89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Crispin","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaad.2016.12.004_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","article-title":"Tofacitinib for the treatment of alopecia areata and variants in adolescents","volume":"76","author":"Craiglow","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib30","doi-asserted-by":"crossref","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaad.2016.12.004_bib31","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamadermatol.2015.4445","article-title":"Topical ruxolitinib for the treatment of alopecia universalis","volume":"152","author":"Craiglow","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib32","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jaad.2015.09.045","article-title":"A systematic review of pulse steroid therapy for alopecia areata","volume":"74","author":"Shreberk-Hassidim","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jdermsci.2015.01.004","article-title":"The genetics of alopecia areata: new approaches, new findings, new treatments","volume":"78","author":"Biran","year":"2015","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2016.12.004_bib34","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","article-title":"The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling","volume":"136","author":"Amano","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2016.12.004_bib35","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jdermsci.2016.09.007","article-title":"JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation","volume":"84","author":"Amano","year":"2016","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2016.12.004_bib36","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1038\/jid.2011.140","article-title":"Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation","volume":"131","author":"Fridman","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib37","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000347184","article-title":"Effects of the Janus kinase inhibitor CP-690550 (tofacitinib) in a rat model of oxazolone-induced chronic dermatitis","volume":"91","author":"Fujii","year":"2013","journal-title":"Pharmacology"},{"key":"10.1016\/j.jaad.2016.12.004_bib38","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1124\/jpet.115.223784","article-title":"Topically administered Janus-kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis","volume":"354","author":"Fukuyama","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaad.2016.12.004_bib39","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.4049\/jimmunol.1100649","article-title":"Pyridone 6, a pan-JAK inhibitor, ameliorates allergic skin inflammation of NC\/Nga mice via suppression of Th2 and enhancement of Th17","volume":"187","author":"Nakagawa","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2016.12.004_bib40","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib41","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib42","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib43","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1158\/1078-0432.CCR-14-2758","article-title":"Pharmacologic inhibition of JAK1\/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects","volume":"21","author":"Carniti","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2016.12.004_bib44","doi-asserted-by":"crossref","first-page":"e109799","DOI":"10.1371\/journal.pone.0109799","article-title":"Pharmacologic blockade of JAK1\/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect","volume":"9","author":"Choi","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.jaad.2016.12.004_bib45","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/jid.2013.476","article-title":"Reversal of CD8 T-cell\u2013mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib","volume":"134","author":"Okiyama","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib46","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1182\/blood-2012-01-403196","article-title":"IFN\u03b3R signaling mediates alloreactive T-cell trafficking and GVHD","volume":"120","author":"Choi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2016.12.004_bib47","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/TP.0b013e3181f24e59","article-title":"CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell\u2013mediated acute graft-versus-host disease by inhibiting the interferon-\u03b3 pathway","volume":"90","author":"Park","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.jaad.2016.12.004_bib48","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-016-0298-6","article-title":"Ruxolitinib in steroid refractory graft-vs.-host disease: a case report","volume":"9","author":"Maffini","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jaad.2016.12.004_bib49","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/bmt.2016.256","article-title":"Ruxolitinib treatment for GvHD in patients with myelofibrosis","volume":"51","author":"Mori","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaad.2016.12.004_bib50","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2016.12.004_bib51","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jaad.2016.12.004_bib52","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1177\/0961203316640910","article-title":"Safety, tolerability, efficacy and\u00a0pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus","volume":"25","author":"Kahl","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2016.12.004_bib53","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1182\/blood-2015-08-662353","article-title":"Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma","volume":"127","author":"Willerslev-Olsen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2016.12.004_bib54","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.4161\/cc.24987","article-title":"STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma","volume":"12","author":"Kopp","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jaad.2016.12.004_bib55","doi-asserted-by":"crossref","first-page":"45730","DOI":"10.18632\/oncotarget.10160","article-title":"STAT5 induces miR-21 expression in cutaneous T cell lymphoma","volume":"7","author":"Lindahl","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaad.2016.12.004_bib56","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/leu.2011.198","article-title":"Constitutive activation of STAT3 in S\u00e9zary syndrome is independent of SHP-1","volume":"26","author":"McKenzie","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jaad.2016.12.004_bib57","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/sj.jid.5701246","article-title":"Cucurbitacin I inhibits Stat3 and induces apoptosis in Sezary cells","volume":"128","author":"van Kester","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib58","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1073\/pnas.94.13.6764","article-title":"Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines","volume":"94","author":"Nielsen","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2016.12.004_bib59","first-page":"901","article-title":"Pulmonary cryptococcosis in the setting of tofacitinib therapy for psoriasis","volume":"14","author":"Seminario-Vidal","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib60","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/rheumatology\/keu172","article-title":"Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies","volume":"53","author":"Souto","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2016.12.004_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12895-015-0025-y","article-title":"Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis","volume":"15","author":"Valenzuela","year":"2015","journal-title":"BMC Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib62","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/bjd.12517","article-title":"Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment","volume":"169","author":"Strober","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib63","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jdv.13114","article-title":"Tofacitinib, a novel JAK3 inhibitor, as a potential cause of distal symmetric polyneuropathy","volume":"30","author":"Zeidler","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2016.12.004_bib64","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","article-title":"Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis","volume":"39","author":"Clowse","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2016.12.004_bib65","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jaad.2016.06.012","article-title":"Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis","volume":"75","author":"Wu","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib66","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/1346-8138.13404","article-title":"Case of disseminated molluscum contagiosum caused by ruxolitinib, a Janus kinase 1 and 2 inhibitor","volume":"43","author":"Kinoshita","year":"2016","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib67","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.jaad.2013.09.035","article-title":"Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment","volume":"70","author":"Tong","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2016.12.004_bib68","article-title":"Drug-associated skin lesions in a patient with\u00a0myelofibrosis receiving ruxolitinib","volume":"20","author":"Fournier","year":"2014","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2016.12.004_bib69","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1177\/0961203315573347","article-title":"DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184","volume":"24","author":"van Vollenhoven","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2016.12.004_bib70","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/bjd.13922","article-title":"Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with ruxolitinib","volume":"173","author":"Fabiano","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib71","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib72","first-page":"252","article-title":"Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions","volume":"13","author":"Menter","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib73","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/jdv.12081","article-title":"Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis","volume":"28","author":"Mamolo","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2016.12.004_bib74","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/09546634.2013.861891","article-title":"The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib","volume":"26","author":"Bushmakin","year":"2015","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jaad.2016.12.004_bib75","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/09546634.2014.906033","article-title":"Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: clinically important difference and responder analyses","volume":"26","author":"Mamolo","year":"2015","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jaad.2016.12.004_bib76","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib77","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study","volume":"74","author":"Papp","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib78","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jaci.2015.12.1318","article-title":"Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: a randomized phase 2 study","volume":"137","author":"Krueger","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2016.12.004_bib79","first-page":"568","article-title":"Efficacy of tofacitinib for the treatment of moderate-to-severe chronic plaque psoriasis in patient subgroups from two randomised phase 3 trials","volume":"15","author":"Menter","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib80","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/jdv.13702","article-title":"Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a phase 3 study","volume":"30","author":"Valenzuela","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2016.12.004_bib81","first-page":"1","article-title":"Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis","volume":"18","author":"Tan","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2016.12.004_bib82","doi-asserted-by":"crossref","unstructured":"Griffiths C, Vender R, Sofen H, et al. Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a phase 3 study in patients with moderate to\u00a0severe chronic plaque psoriasis. J Eur Acad Dermatol Venereol. http:\/\/dx.doi.org\/10.1111\/jdv.13808, published online September 7, 2016.","DOI":"10.1111\/jdv.13808"},{"key":"10.1016\/j.jaad.2016.12.004_bib83","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/jid.2014.260","article-title":"Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis","volume":"134","author":"Craiglow","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib84","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.23871","article-title":"Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia","volume":"90","author":"Pieri","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaad.2016.12.004_bib85","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/jamadermatol.2015.3772","article-title":"Tofacitinib citrate for the treatment of nail dystrophy associated with alopecia universalis","volume":"152","author":"Dhayalan","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib86","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/jdv.13598","article-title":"Efficacy of tofacitinib in treatment of alopecia universalis in two patients","volume":"30","author":"Gupta","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2016.12.004_bib87","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/exd.13060","article-title":"Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers","volume":"25","author":"Jabbari","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib88","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000445182","article-title":"Transient efficacy of tofacitinib in alopecia areata universalis","volume":"8","author":"Anzengruber","year":"2016","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib89","doi-asserted-by":"crossref","unstructured":"Mrowietz U, Gerdes S, Gl\u00e4ser R, Schr\u00f6der O. Successful treatment of refractory alopecia areata universalis and psoriatic arthritis, but not of plaque psoriasis with tofacitinib in a young woman. Acta Derm Venereol. http:\/\/dx.doi.org\/10.2340\/00015555-2491, published online June 28, 2016.","DOI":"10.2340\/00015555-2491"},{"key":"10.1016\/j.jaad.2016.12.004_bib90","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2015.06.045","article-title":"Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate","volume":"73","author":"Levy","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib91","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jaci.2014.12.1867","article-title":"Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation","volume":"135","author":"Higgins","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2016.12.004_bib92","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/cid\/ciw020","article-title":"Ruxolitinib induces interleukin 17 and ameliorates chronic mucocutaneous candidiasis caused by STAT1 gain-of-function mutation","volume":"62","author":"M\u00f6ssner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2016.12.004_bib93","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1056\/NEJMc1412997","article-title":"Remission of recalcitrant dermatomyositis treated with ruxolitinib","volume":"371","author":"Hornung","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2016.12.004_bib94","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib95","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jaad.2015.10.007","article-title":"Failure to thrive, interstitial lung disease, and progressive digital necrosis with onset in infancy","volume":"74","author":"Chia","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2016.12.004_bib96","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.jaci.2016.07.015","article-title":"Efficacy of the Janus kinase 1\/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children","volume":"138","author":"Fr\u00e9mond","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2016.12.004_bib97","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jid.2016.02.015","article-title":"JAK1\/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus","volume":"136","author":"Wenzel","year":"2016","journal-title":"J Invest Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216311872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962216311872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:42:33Z","timestamp":1759272153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962216311872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":97,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0190962216311872"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2016.12.004","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Janus kinase inhibitors in dermatology: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2016.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}